Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Tom DuBois who wrote (3287)	12/11/1997 12:50:00 PM
From: Izzy	Respond to of 6136

Tom, thanks. FWIW, I have just talked with a Dr. from Murex Diagnostics (MURXF), who has the LiPA HIV-1 Reverse Transcriptase (RT) test for the rapid assay in identifying HIV resistance to AZT, dd, ddC, and 3TC. In the US, its use is for research only, but, in other countries, it is being used clinically. I am told that there is going to be a test available soon to detect PI drug resistance. It appears that the company plans on receiving FDA approval in 1998. In addition, the company offers wonderful, educational materials (even I learned something). Phone numbers: 1-800-6330171, ext 211 (Dr. Shockley) and 310-5689895 (Dr. Blatt, National Genetics Institute). It is my initial thinking that all patients, naive and on treatment, should have drug testing for resistance so that appropriate drugs can be prescribed, monitored, and adjusted.